Zacks Investment Research on MSN
GSK (GSK) reports next week: Wall Street expects earnings growth
GSK (GSK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...
Zacks Investment Research on MSN
Here's why GSK (GSK) is a strong growth stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still undervalued vs. peers. Read the full analysis here.
GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc (NYSE:GSK) on January 7 and set a price target of $55.60. The same day, GSK plc ...
GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...
GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...
The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...
Zacks.com on MSN
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results